ProPhase Labs (NASDAQ:PRPH) Shares Pass Below Two Hundred Day Moving Average – Time to Sell?

ProPhase Labs, Inc. (NASDAQ:PRPH) shares passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $0.26 and traded as low as $0.0750. ProPhase Labs shares last traded at $0.0756, with a volume of 4,041 shares changing hands.

ProPhase Labs Stock Up 0.8%

The company has a debt-to-equity ratio of 0.14, a quick ratio of 0.14 and a current ratio of 0.14. The firm’s 50-day moving average is $0.11 and its two-hundred day moving average is $0.26. The stock has a market cap of $455,263.20, a P/E ratio of -0.02 and a beta of 0.09.

Hedge Funds Weigh In On ProPhase Labs

An institutional investor recently raised its position in ProPhase Labs stock. Susquehanna International Group LLP increased its position in shares of ProPhase Labs, Inc. (NASDAQ:PRPH) by 290.1% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 397,914 shares of the company’s stock after acquiring an additional 295,899 shares during the quarter. Susquehanna International Group LLP owned about 0.96% of ProPhase Labs worth $182,000 as of its most recent SEC filing. 9.45% of the stock is owned by institutional investors and hedge funds.

ProPhase Labs Company Profile

ProPhase Labs, Inc is a U.S.-based specialty health sciences company that develops, manufactures and markets a range of diagnostic and therapeutic products. The company’s operations span infectious disease testing services, over-the-counter remedies and contract manufacturing for pharmaceutical and consumer health clients. ProPhase Labs leverages both in-house production facilities and distribution networks to bring targeted solutions to market.

In its diagnostics division, ProPhase Labs offers laboratory-based testing for respiratory and infectious diseases, employing molecular and immunoassay technologies.